The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1686
Addendum: Gabapentinoids and Renal Impairment
Download PDF:   US English
Med Lett Drugs Ther. 2023 Oct 2;65(1686):160   doi:10.58347/tml.2023.1686e
Disclosures
Objective(s)
 Select a term to see related articles  gabapentin   Lyrica   Neurontin   pregabalin 

A nephrologist and longtime reader of The Medical Letter wrote us to say that our recent article entitled Drugs for Anxiety Disorders should have said more about the need for dosage adjustment of gabapentin (Neurontin, and others) and pregabalin (Lyrica, and others) in patients with renal impairment. Both drugs, he pointed out, are exclusively renally eliminated and can accumulate in patients with diminished renal function. Symptoms, which can include altered mental status, may develop so slowly that neither the patient nor the practitioner connect them to the drug. The resolution of adverse effects upon discontinuation can be slow.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article